Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
obesity drugs
Biotech
Novo seeks obesity refresh with $550M Replicate deal
Novo will fund Replicate’s RNA research in return for the exclusive, global right to develop and commercialize resulting cardiometabolic programs.
Darren Incorvaia
Aug 28, 2025 7:00am
Viking hits stormy seas as phase 2 oral obesity data sink stock
Aug 19, 2025 9:44am
Response's ex-Sanofi asset hits goal in post-GLP-1 patients
Aug 13, 2025 9:14am
Lilly's oral GLP-1 tied to 12% weight loss in phase 3 trial
Aug 7, 2025 6:30am
Terns vows to stop funding metabolic disease trials beyond 2025
Aug 6, 2025 6:20am
Mice given a brain protein lost weight without getting nauseous
Jul 24, 2025 7:00am